



January 30, 2024

BSE Limited

Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 ('Listing Regulations').

We are pleased to enclose a Press release regarding introduction of the world's first-ever Digital Therapeutics Certificate for Cardiologists in India by Lupin Digital Health in collaboration with the American College of Cardiology.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl: a/a

Press Release

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin Digital Health introduces Digital Therapeutics Certificate for Cardiologists in India in collaboration with the American College of Cardiology

Mumbai, Washington DC, January 30, 2024: Lupin Digital Health, India's first evidence-based cardiology Digital Therapeutics (DTx) platform and the American College of Cardiology (ACC), the global scientific leader in the practice of Cardiology, have announced the introduction of the world's first-ever Digital Therapeutics Certificate for Cardiologists. This unveiling took place during the Platinum Jubilee celebration event of the Cardiology Society of India (CSI) in Kolkata.

Dr. Edward Fry, the Past President of ACC, attended the event, emphasizing the global significance of this collaboration in advancing cardiovascular patient care. In a bid to encourage the integration of cutting-edge digital solutions in Cardiology, ACC will grant 'Digital Pioneer' certificates to cardiologists who adopt Remote Cardiac Rehab and Digital Heart Failure clinic solutions, acknowledging their commitment to innovation and patient-centered healthcare. This collaboration is crucial in ensuring top-notch care and enhancing outcomes, all from the convenience of patients' homes.

Expressing enthusiasm about this initiative, **Rajeev Sibal, President - India Region Formulations, Lupin** stated, "Lupin is proud to support cardiologists with our patient-centric solutions. As a pioneer in the DTx space, we are delighted to play a pivotal role in bringing this important ACC certificate to cardiologists and setting new standards in digital therapeutics."

Sidharth Srinivasan, CEO, Lupin Digital Health added, "The collaboration with the American College of Cardiology marks a transformative milestone in remote cardiac rehabilitation. A growing number of doctors and cardiac institutes are acknowledging Remote Cardiac Rehab as a foundational pillar in making cardiac care more accessible. We are sure that this initiative will further encourage the healthcare fraternity to better understand and utilize technology-led Cardiac Rehab."

Ami Bhatt, MD, ACC Chief Innovation Officer, highlighted the broader impact, "The ACC is proud to recognize cardiologists who are pioneering digital therapeutics adaptation in India through Lupin Digital Health's Lyfe platform. This recognition underscores our commitment to advancing digital solutions that improve patient outcomes globally."

Lyfe, developed by Lupin Digital Health, is India's first clinically proven remote cardiac rehabilitation program. Addressing the underutilization of cardiac rehabilitation, Lyfe is trusted by over 450

Press Release

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

cardiologists with patients across 250 towns and cities in India. The program has demonstrated its effectiveness in enhancing heart health and improving the quality of life for cardiovascular patients.

This collaboration is a significant step forward in global healthcare, aligning with the mission of both Lupin Digital Health and the American College of Cardiology to revolutionize cardiovascular patient care through innovative digital solutions.

About American College of Cardiology

The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all. As the preeminent source of professional medical education for the entire cardiovascular care team since 1949, ACC credentials cardiovascular professionals in over 140 countries who meet stringent qualifications and leads in the formation of health policy, standards, and guidelines. Through its world-renowned family of JACC Journals, NCDR registries, ACC Accreditation Services, global network of Member Sections, CardioSmart patient resources and more, the College is committed to ensuring a world where science, knowledge and innovation optimize patient care and outcomes. Learn more at www.ACC.org or follow @ACCinTouch.

About Lupin Digital Health

Lupin Digital Health, a fully owned subsidiary of Lupin Limited, a leading global pharmaceutical company, is dedicated to developing cutting-edge digital health solutions that address unmet patient needs. Their flagship product, Lyfe, is a revolutionary digital therapeutics solution that harnesses the power of artificial intelligence (AI) and machine learning (ML) to deliver personalized and immersive patient experiences. Lyfe aims to tackle the critical challenge of effectively managing chronic diseases, thereby reducing the risks and expenses associated with hospitalization. By offering timely guidance on various health parameters, Lyfe empowers individuals to take charge of their well-being. With its seamless integration of health monitoring devices, widespread technological accessibility, and the expertise of renowned cardiologists, Lyfe provides a comprehensive cardiac care solution that enables individuals to regain control over their health and reshape the future of patient care. Please visit <https://lyfe.in/> for more information.

Follow us on LinkedIn: <https://www.linkedin.com/company/lupin-digital-health/>

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's

Press Release

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on:

Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

For further information or queries, please contact –

Priyanka Chavda

Manager – Corporate Communications

Email: priyankachavda@lupin.com